Medicine & Life Sciences

1. Multiple Myeloma 100%
2. Chimeric Antigen Receptors 78%
3. Immunoglobulin Light-chain Amyloidosis 54%
4. Survival 41%
5. Cell- and Tissue-Based Therapy 41%
6. axicabtagene ciloleucel 40%
7. T-Lymphocytes 37%
8. B-Cell Lymphoma 28%
9. Plasma Cells 23%
10. Amyloidosis 23%
11. Cytokine Release Syndrome 20%
12. Stem Cell Transplantation 18%
13. Therapeutics 18%
14. Lymphoma 17%
15. Progression-Free Survival 17%
16. Light 16%
17. Monocytes 15%
18. Non-Hodgkin's Lymphoma 14%
19. Dexamethasone 13%
20. Waldenstrom Macroglobulinemia 12%
21. B-Cell Maturation Antigen 11%
22. Transplants 11%
23. CD19 Antigens 10%
24. POEMS Syndrome 9%
25. Proteasome Inhibitors 9%
26. Smoldering Multiple Myeloma 8%
27. Bortezomib 8%
28. Adoptive Immunotherapy 8%
29. Flow Cytometry 8%
30. Bone Marrow Cells 8%
31. Immunoglobulins 7%
32. Clinical Trials 7%
33. Immunosuppressive Agents 7%
34. Lenalidomide 7%
35. Neoplasms 7%
36. Plasma Cell Leukemia 7%
37. Fluorescence In Situ Hybridization 7%
38. Confidence Intervals 7%
39. Bone Marrow 7%
40. Stem Cells 6%
41. Rituximab 6%
42. Amyloid 6%
43. Residual Neoplasm 6%
44. Cyclophosphamide 6%
45. Immunotherapy 6%
46. Safety 6%
47. Drug Therapy 6%
48. Serum 5%
49. Immunoglobulin Light Chains 5%
50. pomalidomide 5%